NO941546L - Transdermale butyrofenonblandinger - Google Patents

Transdermale butyrofenonblandinger

Info

Publication number
NO941546L
NO941546L NO941546A NO941546A NO941546L NO 941546 L NO941546 L NO 941546L NO 941546 A NO941546 A NO 941546A NO 941546 A NO941546 A NO 941546A NO 941546 L NO941546 L NO 941546L
Authority
NO
Norway
Prior art keywords
butyrophenone
transdermal
carboxylic acid
mixture
composition
Prior art date
Application number
NO941546A
Other languages
English (en)
Other versions
NO941546D0 (no
Inventor
Toshiyuki Takayasu
Hideo Saitoh
Eiichi Mafune
Original Assignee
Daiichi Seiyaku Saitama
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Saitama, Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Saitama
Publication of NO941546D0 publication Critical patent/NO941546D0/no
Publication of NO941546L publication Critical patent/NO941546L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Transdermal butyrofenonblanding som omfatter de folgende bestanddeler: (a) til (f): (a) en vannløselig polymer som består av en monomer inneholdende, helt eller delvis, alifatisk karboksylsyre med en polymeriserbar dobbelbinding eller et salt av kar- boksylsyren, (b) et kryssbindingsmiddel, (c) en kryssbindingspromoter, (d) vann, (e) et butyrofenonlegemiddel, og (f) et løsningsmiddel for butyrofenonlegemidlet (e), som vesentlige bestanddeler. Blandingens pH justeres til å falle i området 5,5 til 8,0. Med blandingen ifølge oppfinnelsen kan konsentrasjonen av den aktive butyrofenonbestanddelen i blod kontrolleres. Blandingen kan utøve sin primære virkning, antibreknings- virkning, uten å forårsake utslett i huden og med mindre uheldige bivirkninger.
NO941546A 1993-04-28 1994-04-27 Transdermale butyrofenonblandinger NO941546L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10295893 1993-04-28

Publications (2)

Publication Number Publication Date
NO941546D0 NO941546D0 (no) 1994-04-27
NO941546L true NO941546L (no) 1994-10-31

Family

ID=14341312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941546A NO941546L (no) 1993-04-28 1994-04-27 Transdermale butyrofenonblandinger

Country Status (8)

Country Link
US (1) US5478568A (no)
EP (1) EP0622074A1 (no)
CN (1) CN1097303A (no)
AU (1) AU667161B2 (no)
CA (1) CA2121991A1 (no)
FI (1) FI941972A (no)
NO (1) NO941546L (no)
TW (1) TW260614B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1081030C (zh) * 1996-02-07 2002-03-20 立德化学株式会社 含有曲尼司特的外用制剂及其制备方法
US6278237B1 (en) 1997-09-22 2001-08-21 Emagin Corporation Laterally structured high resolution multicolor organic electroluminescence display device
US6211296B1 (en) 1998-11-05 2001-04-03 The B. F. Goodrich Company Hydrogels containing substances
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
WO2001030337A2 (en) * 1999-10-22 2001-05-03 Orbon Corporation Ophthalmic formulation of dopamine antagonists
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
IT1319210B1 (it) * 2000-10-13 2003-09-26 Italiano Biochimico Lisapharma Pellicola per la somministrazione dermica e transdermica di principiattivi.
DE10328942A1 (de) * 2003-06-27 2005-01-27 Lts Lohmann Therapie-Systeme Ag Transmukosale Darreichungsformen mit verminderter Schleimhautirritation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
JPS60226808A (ja) * 1985-03-11 1985-11-12 Watanabe Yakuhin Kogyo Kk シツプ薬
DE3910543A1 (de) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
JP2839164B2 (ja) * 1989-12-25 1998-12-16 帝國製薬株式会社 消炎鎮痛貼付剤
JPH03232817A (ja) * 1990-02-07 1991-10-16 Showa Yakuhin Kako Kk 貼付剤
JP2647222B2 (ja) * 1990-02-27 1997-08-27 積水化学工業株式会社 経皮吸収製剤

Also Published As

Publication number Publication date
CA2121991A1 (en) 1994-10-29
EP0622074A1 (en) 1994-11-02
FI941972A (fi) 1994-10-29
AU667161B2 (en) 1996-03-07
AU5938694A (en) 1994-11-03
US5478568A (en) 1995-12-26
FI941972A0 (fi) 1994-04-28
NO941546D0 (no) 1994-04-27
CN1097303A (zh) 1995-01-18
TW260614B (no) 1995-10-21

Similar Documents

Publication Publication Date Title
Lorenz et al. Histamine release in human subjects by modified gelatin (Haemaccel) and dextran: an explanation for anaphylactoid reactions observed under clinical conditions?
Brimble et al. Histamine H1 and H2-receptors at a ganglionic synapse
NO883591L (no) Dermal administrasjonsform.
ATE94877T1 (de) Piperazinylderivate von purinen und deren isostere als hypoglykaemische wirkstoffe.
MX9802734A (es) Nuevas formulaciones liquidas estables a base de paracetamol y su modo de preparacion.
EP0747092A3 (en) Dissolution liquid for drug in iontophoresis
KR950700072A (ko) 클린다마이신과 벤조일 페록사이드를 함유한 좌창 치료용 조성물(Composi-tions of clindamycin and benzoyl peroxide for acne treatment)
DE69401945T2 (de) Einarbeitung eines poly-n-vinylamids in ein transdermales system
CH664495A5 (de) Pharmazeutische formulierung.
DE69428295T2 (de) Perkutane Behandlung mit Mastzelldegranulatoren zur Behandlung von Reizstoffüberempfindlichkeit
DE69424537T2 (de) Therapeutischer wirkstoff zur behandlung von melanomen
ATE241368T1 (de) Präparation und stabilisation von zellen
NO941546L (no) Transdermale butyrofenonblandinger
CH665356A5 (de) Pharmazeutische formulierung.
FR2385506A1 (fr) Procede de traitement du bois par un agent de preservation du bois et bois traite par ledit agent de preservation du bois
DE69737500T2 (de) Gereinigte Multimerase
KR880007089A (ko) 약리학용/화장용 약제(Pharmacological/Cosmetic Preparation)
KR910005877A (ko) 얼굴표피 및 신체의 피부부위의 보기 흉한 결함증상을 경감하기 위한 탈증합된 데옥시리보핵산을 함유하는 국소용 조성물
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
Craddock et al. Amino acid-activating enzymes in rat-liver mitochondria
ATE177942T1 (de) Lösung, die igf-1 enthält
DK0483614T3 (da) Anvendelse af aminosyrer til beskyttelse af og metabolisk restitution af iskæmisk hjertevæv
Saruta et al. Effects of angiotensin-converting enzyme inhibitors on the vascular response to norepinephrine
GB1507643A (en) 4-(5-nitro-2-furyl)quinaldinic acid n-oxide and its use in the treatment of bovine mastitis
Rosenthal et al. Hemodynamic and renin responses to somatostatin in essential hypertension